🇺🇸 FDA
Pipeline program

De-escalation to ticagrelor 60 mg at day 30

2023/01

Phase 3 small_molecule active

Quick answer

De-escalation to ticagrelor 60 mg at day 30 for Non ST Segment Elevation Acute Coronary Syndrome is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
COLLEGIUM PHARMACEUTICAL, INC
Indication
Non ST Segment Elevation Acute Coronary Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials